Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas

StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Feb 28, 2031 → May 31, 2031
See other at-risk trials from Washington University School of Medicine

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Aug 31, 2026 to Nov 30, 2026 Show 4 more changesShow less
    • Primary completion pushed from Feb 28, 2031 to May 31, 2031
    • Study completion pushed from Aug 31, 2032 to Nov 30, 2032
    • Eligibility criteria expanded, about 42 words
    • Secondary endpoints: details revised at 3 of 8 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study will assess the therapeutic efficacy of the combination of Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to the therapeutic efficacy of the combination of LiTT with physician's choice of adjuvant chemotherapy in patients with recurrent glioblastoma. Patients will be enrolled and randomized on a 2:1 ratio to either the experimental arm (LiTT + cemiplimab) or the control arm (LiTT + physician/s choice chemotherapy).
Trial Details
NCT Number NCT07620548
Lead Sponsor Washington University School of Medicine
Collaborators: Regeneron Pharmaceuticals
Conditions
(from sponsor)		 Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Related terms Glioblastoma, Recurrence
Enrollment 99 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov